This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Catalyst's (CPRX) Q3 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on earnings but misses sales estimates in the third quarter of 2020.
Trillium (TRIL) Soars: Stock Adds 6% in Session
by Zacks Equity Research
Trillium (TRIL) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 39.71% and 63770.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Will Concert Pharmaceuticals (CNCE) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert (CNCE) Upgraded to Buy: Here's Why
by Zacks Equity Research
Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Is Concert Pharmaceuticals (CNCE) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (CNCE) Outperforming Other Medical Stocks This Year?
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
How Concert Pharmaceuticals (CNCE) Stock Stands Out in a Strong Industry
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Catalyst (CPRX) Q1 Earnings Beat Estimates, Revenues Miss
by Zacks Equity Research
Catalyst (CPRX) beats on Q1 earnings but misses on revenues. It also withdraws sales guidance due to the coronavirus pandemic.
Concert Pharmaceuticals (CNCE) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 5.41% and -65.00%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Concert (CNCE) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Concert (CNCE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Why Concert Pharmaceuticals (CNCE) Stock Might be a Great Pick
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 15.29% and -97.14%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Concert Pharmaceuticals (CNCE) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 15.22% and -83.67%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharma's CTP-692 Positive for Schizophrenia in Phase I
by Zacks Equity Research
Concert Pharma (CNCE) reports favorable data from the two early-stage studies on its pipeline candidate, CTP-692, currently under evaluation as an adjunctive treatment for schizophrenia. Share rise.
Earnings Preview: Concert Pharmaceuticals (CNCE) Q1 Earnings Expected to Decline
by Zacks Equity Research
Concert (CNCE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Concert Pharma Initiates Early-Stage Schizophrenia Study
by Zacks Equity Research
Concert Pharmaceuticals (CNCE) announces initiation of multiple-ascending dose phase I study to evaluate its pipeline candidate, CTP-692, as an adjunctive treatment for schizophrenia.
New Strong Sell Stocks for March 25th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.
New Strong Sell Stocks for March 12th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Vertex's VX-445 Triple Combo Cystic Fibrosis Trials Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-445 plus tezacaftor and ivacaftor meet the primary endpoint. The company delays filing for U.S. approval.
Vertex's (VRTX) Triple Combo Cystic Fibrosis Studies Succeed
by Zacks Equity Research
Vertex's (VRTX) two phase III studies evaluating a triple combination regimen of VX-659 plus tezacaftor and ivacaftor meet the primary endpoint. Stock rises almost 5%.
Concert Pharmaceuticals (CNCE) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of -19.35% and -45.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Concert Pharmaceuticals (CNCE) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Concert (CNCE) delivered earnings and revenue surprises of 8.06% and -90.00%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Vertex's Third Cystic Fibrosis Treatment Gets FDA Approval
by Zacks Equity Research
Vertex???s (VRTX) FDA approved tezacaftor/ivacaftor combination for cystic fibrosis in patients with certain mutations in the CFTR gene marks the indication???s third treatment.